190 related articles for article (PubMed ID: 35472201)
1. Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors.
Poorebrahim M; Abazari MF; Moradi L; Shahbazi B; Mahmoudi R; Kalhor H; Askari H; Teimoori-Toolabi L
PLoS Comput Biol; 2022 Apr; 18(4):e1009962. PubMed ID: 35472201
[TBL] [Abstract][Full Text] [Related]
2. Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway.
Yoshikawa Y; Takano O; Kato I; Takahashi Y; Shima F; Kataoka T
Cancer Lett; 2017 Dec; 410():82-91. PubMed ID: 28951129
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors of RAS proteins with oncogenic mutations.
Orgován Z; Keserű GM
Cancer Metastasis Rev; 2020 Dec; 39(4):1107-1126. PubMed ID: 32770300
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
5. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
Rabi T; Catapano CV
Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
[TBL] [Abstract][Full Text] [Related]
6. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.
Hyun S; Shin D
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830024
[TBL] [Abstract][Full Text] [Related]
7. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
8. Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile.
Zhang Z; Morstein J; Ecker AK; Guiley KZ; Shokat KM
J Am Chem Soc; 2022 Sep; 144(35):15916-15921. PubMed ID: 36001446
[No Abstract] [Full Text] [Related]
9. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
10. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.
Indarte M; Puentes R; Maruggi M; Ihle NT; Grandjean G; Scott M; Ahmed Z; Meuillet EJ; Zang S; Lemos R; Du-Cuny L; Layng FIAL; Correa RG; Bankston LA; Liddington RC; Kirkpatrick L; Powis G
Cancer Res; 2019 Jun; 79(12):3100-3111. PubMed ID: 31040156
[TBL] [Abstract][Full Text] [Related]
11. The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways.
Vasseur R; Skrypek N; Duchêne B; Renaud F; Martínez-Maqueda D; Vincent A; Porchet N; Van Seuningen I; Jonckheere N
Biochim Biophys Acta; 2015 Dec; 1849(12):1375-84. PubMed ID: 26477488
[TBL] [Abstract][Full Text] [Related]
12. Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.
Koundinya M; Sudhalter J; Courjaud A; Lionne B; Touyer G; Bonnet L; Menguy I; Schreiber I; Perrault C; Vougier S; Benhamou B; Zhang B; He T; Gao Q; Gee P; Simard D; Castaldi MP; Tomlinson R; Reiling S; Barrague M; Newcombe R; Cao H; Wang Y; Sun F; Murtie J; Munson M; Yang E; Harper D; Bouaboula M; Pollard J; Grepin C; Garcia-Echeverria C; Cheng H; Adrian F; Winter C; Licht S; Cornella-Taracido I; Arrebola R; Morris A
Cell Chem Biol; 2018 Jun; 25(6):705-717.e11. PubMed ID: 29628435
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention.
Karmakar S; Kaushik G; Nimmakayala R; Rachagani S; Ponnusamy MP; Batra SK
Semin Cancer Biol; 2019 Feb; 54():63-71. PubMed ID: 29199014
[TBL] [Abstract][Full Text] [Related]
14. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Chen H; Smaill JB; Liu T; Ding K; Lu X
J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
[TBL] [Abstract][Full Text] [Related]
15. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
16. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
[TBL] [Abstract][Full Text] [Related]
17. Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.
Sakamoto K; Masutani T; Hirokawa T
Sci Rep; 2020 Dec; 10(1):21671. PubMed ID: 33303890
[TBL] [Abstract][Full Text] [Related]
18. K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
Li T; Zheng Y; Sun H; Zhuang R; Liu J; Liu T; Cai W
Med Oncol; 2016 Jul; 33(7):61. PubMed ID: 27225938
[TBL] [Abstract][Full Text] [Related]
19. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology.
Sakamoto K; Kamada Y; Sameshima T; Yaguchi M; Niida A; Sasaki S; Miwa M; Ohkubo S; Sakamoto JI; Kamaura M; Cho N; Tani A
Biochem Biophys Res Commun; 2017 Mar; 484(3):605-611. PubMed ID: 28153726
[TBL] [Abstract][Full Text] [Related]
20. Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers.
Mottini C; Cardone L
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
